Clicky

Anebulo Pharmaceuticals, Inc.(ANEB)

Description: Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.


Keywords: Biotechnology Cannabis Smoking Cannabinoid Addiction Abnormal Psychology

Home Page: www.anebulo.com

ANEB Technical Analysis

1415 Ranch Road 620 South
Lakeway, TX 78734
United States
Phone: 512-598-0931


Officers

Name Title
Dr. Joseph F. Lawler M.D., Ph.D. Founder & Chairman
Mr. Simon J. Allen B.Sc., M.B.A., MBA CEO & Director
Mr. Rex Merchant CFA CFO & Sec.
Dr. Kenneth C. Cundy Ph.D. Chief Scientific Officer
Mr. Scott L. Anderson Head of Investor Relations & Public Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.514
Price-to-Sales TTM: 0
IPO Date: 2021-05-07
Fiscal Year End: December
Full Time Employees: 4
Back to stocks